Eli Lilly and Co
LLY
Company Profile
Business description
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
Contact
Lilly Corporate Center
IndianapolisIN46285
USAT: +1 317 276-2000
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
47,000
Eli Lilly and Co News & Analysis
stocks
2 companies poised to capitalize on the rise of GLP-1 drugs
Why Pfizer and Roche look like top choices for investors in the war to tip the scales.
stocks
The trillion-dollar club: Are these mega-sized stocks still buys?
The biggest stocks got bigger this year, breaking multi-trillion-dollar milestones.
markets
December 2025 US stock market outlook: Where we see investment opportunities
Heading into year-end, Santa Claus Rally or AI exhaustion?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,915.00 | 26.10 | 0.29% |
| CAC 40 | 8,108.43 | 6.31 | -0.08% |
| DAX 40 | 24,046.01 | 17.87 | 0.07% |
| Dow JONES (US) | 47,710.73 | 244.26 | -0.51% |
| FTSE 100 | 9,645.09 | 21.92 | -0.23% |
| HKSE | 25,765.36 | 319.72 | -1.23% |
| NASDAQ | 23,528.10 | 50.03 | -0.21% |
| Nikkei 225 | 50,581.94 | 90.07 | 0.18% |
| NZX 50 Index | 13,486.32 | 2.33 | 0.02% |
| S&P 500 | 6,841.83 | 28.57 | -0.42% |
| S&P/ASX 200 | 8,624.40 | 28.80 | 0.34% |
| SSE Composite Index | 3,924.08 | 21.27 | 0.55% |